Two decades have passed since the late 1970s, which witnessed the introduct
ion of total mesorectal excision (TME)-based operations for rectal cancers
on both sides of the Atlantic. Since the introduction of TME, clinical expe
rience has been reported widely in the form of single- and multisurgeon rep
orts from wide geographic regions with multiple participants, and from spec
ialty services with narrow focus and high levels of expertise. All of these
published results conclude that in comparison with conventionally practice
d blunt surgery for rectal cancer, TME-based (i.e., anatomically correct, s
harply performed) operations are associated with significantly lower rates
of pelvic (local) recurrences, a significantly higher rate of survival, and
significantly lower long-term morbidity. The latter is accomplished throug
h dramatically higher rates of sphincter preservation, and the preservation
of both sexual and urinary functions. Overall, there is a remarkable simil
arity in the clinical results that have been reported from diverse centers.
TME now forms the basis of large randomized clinical trials in which the r
ole of adjuvant therapy is being reexamined. The current status of TME is r
eviewed, and the authors' clinical results of a consecutive series of 544 T
ME-based operations performed through 1998 are updated. (C) 2000 Wiley-Liss
, Inc.